Logo

SNES

SenesTech, Inc.

SNES

SenesTech, Inc. • NASDAQ
$2.91 ▲ 3.56% (+0.10)
Market Cap $15.20 M
52w High $6.24
52w Low $1.30
Dividend Yield 0%
P/E -1.32
Volume 17.37K
Outstanding Shares 5.22M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $690K ▲ $1.78M ▼ $-1.298M ▲ -188.116% ▲ $-0.28 ▲ $-1.263M ▲
Q2-2025 $625K ▲ $2.023M ▲ $-1.616M ▲ -258.56% ▲ $-0.87 ▲ $-1.575M ▲
Q1-2025 $485K ▼ $1.976M ▲ $-1.665M ▼ -343.299% ▼ $-1.28 ▲ $-1.621M ▼
Q4-2024 $501K ▲ $1.562M ▼ $-1.255M ▲ -250.499% ▲ $-2.07 $-1.207M ▲
Q3-2024 $482K $1.862M $-1.513M -313.9% $-2.07 $-1.465M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $10.248M ▲ $14.624M ▲ $3.276M ▼ $11.348M ▲
Q2-2025 $6.055M ▲ $10.365M ▲ $3.388M ▲ $6.977M ▲
Q1-2025 $1.655M ▲ $3.626M ▲ $734K ▼ $2.892M ▲
Q4-2024 $1.307M ▼ $3.278M ▼ $767K ▼ $2.511M ▼
Q3-2024 $2.518M $4.449M $798K $3.651M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.298M ▲ $-1.379M ▼ $-3.006M ▼ $5.608M ▲ $1.223M ▼ $-1.421M ▼
Q2-2025 $-1.616M ▲ $-1.15M ▲ $-47K ▼ $5.597M ▲ $4.4M ▲ $-1.197M ▲
Q1-2025 $-1.665M ▼ $-1.557M ▼ $-36K ▼ $1.941M ▲ $348K ▲ $-1.593M ▼
Q4-2024 $-1.255M ▲ $-1.218M ▲ $-15K ▼ $22K ▼ $-1.211M ▼ $-1.233M ▲
Q3-2024 $-1.513M $-1.399M $0 $1.965M $566K $-1.427M

Five-Year Company Overview

Income Statement

Income Statement SenesTech’s income statement shows a very small, early-stage business that has not yet reached meaningful, consistent revenue and continues to run at a loss. Operating results have been negative year after year, which is typical for a company still investing in commercialization and market development but also signals ongoing financial strain. Earnings per share appear extremely negative largely because of repeated reverse stock splits, which magnify per‑share losses even if the underlying dollar losses are relatively modest. Overall, the company looks firmly in “build and spend” mode rather than “earn and harvest” mode.

Balance Sheet

Balance Sheet The balance sheet looks very thin, with only a modest base of assets and equity and no meaningful debt reported. That suggests the company has been funded mainly through issuing shares rather than borrowing. At the same time, the very small asset base and the history of reverse stock splits point to a fragile financial footing: there is not much cushion if results disappoint or funding conditions tighten. On the positive side, the lack of debt reduces the risk of lenders demanding repayments, but equity holders bear most of the risk and dilution.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, indicating that the core business does not yet pay for itself and the company likely depends on outside capital to keep going. Free cash flow is also negative, though capital spending appears limited, which is typical for an asset‑light, R&D‑driven company. The key question going forward is whether product adoption can grow fast enough, and operating costs can be controlled tightly enough, to narrow these cash outflows before access to new capital becomes difficult or excessively dilutive.

Competitive Edge

Competitive Edge Commercially, SenesTech occupies a unique niche: non‑lethal, fertility‑control solutions for rodent management. It holds EPA registration for its flagship contraceptive product and owns relevant patents, which together create meaningful barriers for direct copycat products. Traditional rodent control giants focus on poisons and lethal methods, so SenesTech is differentiated by being more humane and more environmentally oriented. However, it is a very small player competing against large, well‑funded incumbents with strong distribution, so its success depends heavily on educating the market, proving real‑world effectiveness, and building partnerships faster than competitors can respond.

Innovation and R&D

Innovation and R&D Innovation is clearly the heart of the company. Its products, such as the fertility‑control baits and related delivery systems, introduce a different way to manage rodent populations by suppressing reproduction rather than killing. This is backed by scientific research, patented technology, and regulatory approvals. Recently, management appears to be prioritizing commercialization of existing products, especially the newer soft bait, over launching many new R&D projects, which is a practical move to focus limited resources. The intellectual property portfolio and scientific know‑how give SenesTech a credible technical edge, but turning that innovation into broad customer adoption remains an execution challenge.

Summary

SenesTech is an early‑stage, highly specialized pest‑control company with a distinctive, humane technology platform but a very fragile financial profile. The business has yet to generate meaningful, self‑sustaining revenue and continues to post operating losses and negative cash flow, funded largely through issuing equity, as reflected in repeated reverse stock splits and a lean balance sheet. On the strategic side, its patented, EPA‑approved contraceptive approach to rodent control offers clear differentiation and potential regulatory tailwinds as traditional poisons face more scrutiny. The company’s future hinges on whether it can convert that scientific and regulatory advantage into a commercially scalable business fast enough—by driving adoption of its current products, expanding internationally, and managing costs—while navigating limited financial resources and competition from much larger traditional players.

NEWS

November 11, 2025 · 9:00 AM UTC

SenesTech Expands International Reach with the Addition of the Belize Raptor Center as an Official Distributor of Evolve® Rat Birth Control

Read more

November 10, 2025 · 4:05 PM UTC

SenesTech Reports Third Quarter 2025 Financial Results with Record Revenue and Adjusted EBITDA

Read more

November 10, 2025 · 12:00 PM UTC

SenesTech's Evolve® Rat Birth Control® Now Available Online at Lowes.com

Read more

November 3, 2025 · 4:15 PM UTC

SenesTech to Report Third Quarter 2025 Financial Results on Monday, November 10, 2025

Read more

October 13, 2025 · 8:00 AM UTC

Swampscott Launches Pilot of SenesTech's Innovative Rat Birth Control at Firehouse and Local School

Read more